Doses studied
Kisspeptin dosage in the research record: doses, routes, and half-life
Every figure below is a study protocol in a stated population by a stated route — never a recommendation for human use.
The short version
There is no recommended kisspeptin dosage for personal use, because no kisspeptin product is approved anywhere. What exists is a set of research doses used in supervised studies, and this page reports those as data — what was given, to whom, by which route. The doses are tiny and measured in units like micrograms or nanomoles per kilogram of body weight, not the milligrams you might see on a supplement label. They were delivered by IV drip, IV bolus, under-the-skin injection, or, most recently, a nasal spray. Two facts shape the whole topic. First, the two forms behave very differently: the short form (kisspeptin-10) clears in minutes, while the longer form (kisspeptin-54) lasts much longer. Second, giving it continuously backfires — the receptor tires within days, so spacing matters more than size. None of this is dosing guidance.
Kisspeptin dosage as studied in human trials
Across the published human studies, kisspeptin dosage was always set as a research protocol in a defined population by a defined route. Kisspeptin-54 was infused intravenously in early human studies at roughly 4 pmol/kg/min over 90 minutes; kisspeptin-10 was given to men as a 0.3-1.0 ug/kg IV bolus or a 1.5 ug/kg/h continuous infusion [3]. In women with hypothalamic amenorrhea, kisspeptin-54 was infused at 0.01-1.00 nmol/kg/h [4]. As an IVF oocyte-maturation trigger, kisspeptin-54 was given as a single subcutaneous bolus of 3.2-12.8 nmol/kg, with the best live-birth rate near 9.6 nmol/kg [5]. The 2025 intranasal study used a primary kisspeptin-54 dose of 12.8 nmol/kg [6]. These are listed as study facts; none is a human-use instruction.
Kisspeptin half life
Kisspeptin half life differs dramatically by isoform, and it is the single most important pharmacokinetic fact here. Kisspeptin-10 has a functional half-life of approximately 4 minutes in humans, cleared rapidly by plasma peptidases. Kisspeptin-54 lasts far longer — about 27 to 28 minutes in humans (27.6 +/- 1.1 minutes reported in early work) — because its larger size and greater resistance to endopeptidase cleavage slow its breakdown [3]. That difference is why KP-54 carries the multi-hour clinical applications (IVF triggering, pulse restoration) while KP-10 is favored for short, sharp pharmacological challenges. Paradoxically, KP-10's short half-life may help preserve receptor sensitivity under well-spaced or pulsatile protocols, where continuous exposure would desensitize the receptor [4].
Routes studied, including kisspeptin nasal spray
Four routes appear in the human literature: intravenous bolus, continuous intravenous infusion, subcutaneous injection, and intranasal. The kisspeptin nasal spray is the newest and the only non-invasive one: in 2025, intranasal kisspeptin-54 at 12.8 nmol/kg stimulated LH release in healthy men (+4.4 IU/L), healthy women (+1.4 IU/L), and women with hypothalamic amenorrhea (+4.4 IU/L), with no adverse events and a formulation stable for up to 60 days at 4 degrees C [6]. That result matters because it points toward delivery without an IV line or repeated injections — though, like every route, the nasal data are early-phase and unapproved.
Why dose escalation is the wrong lever: tachyphylaxis
The most consistent dosing lesson across the literature is that more is not better. Chronic twice-daily subcutaneous kisspeptin-54 caused marked tachyphylaxis — the acute LH increment of roughly 24 IU/L on day 1 fell to about 2.5 IU/L by the 14th injection day [14]. High-dose continuous IV infusion (1.0 nmol/kg/h) likewise showed desensitization during the infusion [4]. Receptor sensitivity appears better preserved with well-spaced or pulsatile exposure that mimics the body's own GnRH rhythm. The practical implication, stated as a research observation and not as advice, is that schedule and timing govern the response far more than raw dose.
Isoform identity and why route is dose-shaping
Because the two isoforms differ so much in duration, the route and the form are inseparable from the dose. Kisspeptin-10 (the decapeptide, molecular weight about 1302.5 Da) is cleared in minutes, so the human studies that used it favored a continuous infusion or a bolus chosen to land a sharp, brief LH challenge [3]. Kisspeptin-54 (about 5857 Da, the metastin isoform) lasts long enough for a single subcutaneous bolus to carry a multi-hour effect, which is why it was the form chosen for the IVF oocyte-maturation trigger [5]. The same dose figure therefore means different things by form and route — a number that is a brief pulse for KP-10 can be a sustained exposure for KP-54. Every figure on this page is reported only as the study protocol it came from, in the stated population and by the stated route, and none is a human-use instruction.
Stability and handling in the research record
Formulation stability appears in the literature mainly through the 2025 intranasal work, where the kisspeptin-54 nasal-spray preparation was reported stable for up to 60 days at 4 degrees C — a practical step toward a usable non-injectable product [6]. Kisspeptin-10's shorter functional half-life reflects plasma peptidase activity rather than a storage problem, but it does mean KP-10 is the less durable form in the body once administered [3]. Research-grade lyophilized peptide is typically held cold. None of this constitutes preparation or use guidance; it is reported as the handling context described in the published studies.